Litsea salicifolia Roxb. bark ethanolic extract attenuates rheumatoid arthritis by inhibiting TLR4/NF-κB and activating SIRT1-Nrf2/HO-1 signaling axis: In-vitro and in-vivo evaluations

Anti-inflammatory
DOI: 10.1016/j.phyplu.2022.100390 Publication Date: 2022-12-17T22:59:28Z
ABSTRACT
Litsea salicifolia Roxb. (LS) is a pioneer medicinal plant that can be found in tropical and subtropical countries like India, China Japan. LS traditionally used for treating chronic pulmonary inflammatory diseases asthma wound healing. Also, contains an essential oil with powerful anti-oxidant excite-repellency properties. However, no research findings have been reported about its protective activity on disease rheumatoid arthritis (RA) till yet. This study aims to investigate the anti-rheumatic potential of ethanolic extract (LSE) in-vitro RAW 264.7 cells anti-inflammatory activities in-vivo CFA-induced adjuvant rat model. The chemical characterization LSE was identified by using LC-MS/MS. effects stimulated LPS 1 µg/ml were investigated therapeutic effects. Freund's complete (CFA) induced 100 µl CFA intradermally administered rats. 200 mg/kg orally from day1 day 28. Parameters such as paw volumes measured, X-ray radiography analysis, status, Gene expression studies, western blot analysis histological performed check LSE. Our results revealed at 5 μg/ml 10 reduced LPS-induced oxidative stress burden evidenced ROS levels improved endogenous anti-oxidants Nrf2 SIRT1 cells. inhibited pro-inflammatory cytokines IL-1β, IL-6 TNF-α, PGE2, COX-2 NO murine macrophage dose dependent manner. significantly attenuated inflammation restoring body weight, index, nitrosative lipid peroxidation assays. treatment pannus formation bone erosion histopathology joint tissues. Additionally inflammation-mediated protein TLR4, NF-κB, iNOS Nrf2/HO-1/SIRT1 tissues immunoblotting. alleviated RA through properties inhibiting TLR4-mediated NF-κB nuclear translocation activating Nrf2/SIRT1 signaling pathways, according our findings.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (36)
CITATIONS (6)